Clinical Trials on Neuroendocrine Carcinomas

Total 26364 results

National Health Research Institutes, Taiwan
National Taiwan University Hospital; Chang Gung Memorial Hospital; Kaohsiung... and other collaborators

Completed

Phase II Study to Evaluate the Efficacy and Safety of TLC388 for Differentiated Neuroendocrine Carcinomas Patients

Neuroendocrine Carcinomas

Taiwan
National Cancer Institute, Naples

Completed

Temozolomide for Second-Line Treatment of Neuroendocrine Carcinomas (TENEC)

Neuroendocrine Carcinomas

Italy
University of Turin, Italy

Unknown

Bevacizumab Plus Somatostatin Analogue and Metronomic Capecitabine in Patients With Advanced Neuroendocrine Tumors (XELBEVOCT)

Neuroendocrine Carcinomas

Italy
Fundación de investigación HM
Syntax for Science, S.L

Recruiting

A Clinical Study to Assess the Combination of Two Drugs (177Lu-DOTATATE and Nivolumab) in Neuroendocrine Tumours

Neuroendocrine Tumours (NET) | Neuroendocrine Carcinomas (NEC)

Spain
The Netherlands Cancer Institute

Active, not recruiting

Cisplatinum and Everolimus in Patients With Metastatic or Unresectable NEC of Extrapulmonary Origin

Neuroendocrine Carcinomas

Netherlands
Barwon Health
Australasian Gastro-Intestinal Trials Group; Deakin University; Specialised Therapeutics...

Unknown

A Feasibility Study Of NAB-Paclitaxel In Combination With Carboplatin As First Line Treatment Of Gastrointestinal Neuroendocrine Carcinomas (NABNEC)

Gastrointestinal Neuroendocrine Carcinomas

Australia
Hospices Civils de Lyon

Active, not recruiting

Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer (BEVANEC)

Neuroendocrine Carcinomas

France
Zhejiang University

Completed

Epiction of the Genomic and Genetic Landscape Identifies CCL5 as a Protective Factor in Colorectal Neuroendocrine Carcinoma

Colorectal Neuroendocrine Carcinomas (CRNEC); Genomic Landscape; Genetic Landscape; Prognosis; CCL5; PAX5
Jazz Pharmaceuticals

Completed

Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors (EMERGE-201) (EMERGE-201)

Advanced Solid Tumor | Metastatic Solid Tumor | Urothelial Cancer | Poorly Differentiated Neuroendocrine Carcinomas | Homologous Recombination Deficient-Positive Malignancies Agnostic

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of XL184 (Cabozantinib), Nivolumab, and Ipilimumab for Poorly Differentiated Neuroendocrine Tumors

Metastatic Neuroendocrine Neoplasm | Metastatic Neuroendocrine Carcinoma | Metastatic Large Cell Neuroendocrine Carcinoma | Metastatic Small Cell Neuroendocrine Carcinoma

United States, Canada
H. Lee Moffitt Cancer Center and Research Institute

Terminated

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

Pancreatic Cancer | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinomas of Pancreas | Islet Cell Carcinoma

United States
National Cancer Institute (NCI)

Recruiting

Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the Lung

Advanced Extrapulmonary Neuroendocrine Carcinoma | Metastatic Extrapulmonary Neuroendocrine Carcinoma | Recurrent Extrapulmonary Neuroendocrine Carcinoma | Unresectable Extrapulmonary Neuroendocrine Carcinoma

United States
Roswell Park Cancer Institute
Ipsen

Active, not recruiting

Liposomal Irinotecan, Fluorouracil and Leucovorin in Treating Patients With Refractory Advanced High Grade Neuroendocrine Cancer of Gastrointestinal, Unknown, or Pancreatic Origin

Unresectable Pancreatic Neuroendocrine Carcinoma | Locally Advanced Digestive System Neuroendocrine Carcinoma | Locally Advanced Pancreatic Neuroendocrine Carcinoma | Metastatic Digestive System Neuroendocrine Carcinoma | Metastatic Pancreatic Neuroendocrine Carcinoma | Refractory Digestive... and other conditions

United States
M.D. Anderson Cancer Center

Recruiting

Phase II Trial of Immunotherapy in Patients With Carcinomas Arising From the Renal Medulla

Renal Medullary Carcinoma | Carcinomas

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Recruiting

Lenvatinib Plus Pembrolizumab in Well Differentiated G3 Neuroendocrine Tumors

Neuroendocrine Tumors | High Grade Neuroendocrine Carcinoma, Any Site | Well-Differentiated Neuroendocrine Carcinoma

United States
Amr Mohamed MD
Novatek Pharmaceuticals

Active, not recruiting

NP-101 (TQ Formula) With Nivolumab and Ipilimumab in Advanced or Metastatic Extra-pulmonary Neuroendocrine Carcinomas

Neuroendocrine Carcinoma | Gastroenteropancreatic Neuroendocrine Tumor | Gastroenteropancreatic Neuroendocrine Neoplasm | Mixed Neuroendocrine-Non Neuroendocrine Neoplasm

United States
AIO-Studien-gGmbH
Novartis Pharmaceuticals; Assign Data Management and Biostatistics GmbH

Completed

Safety and Tolerability of Everolimus as Second-line Treatment in Poorly Differentiated Neuroendocrine Carcinoma / Neuroendocrine Carcinoma G3 (WHO 2010) and Neuroendocrine Tumor G3 - an Investigator Initiated Phase II Study (EVINEC)

Neuroendocrine Carcinoma, Grade 3 | Poorly Differentiated Malignant Neuroendocrine Carcinoma | Neuroendocrine Carcinoma, Grade 1 [Well-differentiated Neuroendocrine Carcinoma] That Switched to G3 | Neuroendocrine Carcinoma, Grade 2 [Moderately Differentiated Neuroendocrine Carcinoma]... and other conditions

Germany
Fujian Medical University

Completed

the Optimal Surveillance Frequency for Patients With Gastric Neuroendocrine Carcinoma

Gastric Neuroendocrine Carcinoma

China
Samsung Medical Center
Merck KGaA, Darmstadt, Germany

Completed

Phase II Study of Avelumab in Metastatic Gastronetro-pancreatic （GEP） Neuroendocrine Carcinoma （NEC, WHO Grade 3） as Second-line Treatment After Failing to Etoposide+Cisplatin: Integration of Genomic Analysis to Identify Predictive Molecular Subtypes (MS100070-0177)

Neuroendocrine Carcinoma, Grade 3

Korea, Republic of
Peking Union Medical College Hospital
Harbin Medical University; The First Affiliated Hospital of Xiamen University

Recruiting

Chidamide Plus Sintilimab for Chemotherapy-refractory Advanced High-grade Neuroendocrine Neoplasm

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 3

China
TaiRx, Inc.

Active, not recruiting

Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors

Neuroendocrine Tumors | Gastro-enteropancreatic Neuroendocrine Tumor | Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor | Lung Neuroendocrine Neoplasm

Taiwan
University of Michigan Rogel Cancer Center

Recruiting

Multicenter Trial of ESK981 in Patients With Select Solid Tumors

Pancreatic Adenocarcinoma | Pancreatic Neuroendocrine Tumor | Pancreatic Neuroendocrine Carcinoma | Adenosquamous Carcinoma | Gastrointestinal Neuroendocrine Tumor | Gastrointestinal Neuroendocrine Carcinoma | Neuroendocrine Prostate Carcinoma

United States
Gruppo Oncologico Italiano di Ricerca Clinica

Recruiting

Durvalumab With Carboplatin and Etoposide Chemotherapy in Pulmonary Large-cell Neuroendocrine Carcinoma (LCNEC) (DUPLE)

Pulmonary Large-cell Neuroendocrine Carcinoma

Italy
Rigshospitalet, Denmark

Enrolling by invitation

Dual 64Cu-DOTATATE and 18F-FDG PET/CT Imaging of Patients With Neuroendocrine Neoplasms

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Carcinoma Metastatic | GEP-NET

Denmark
University of Roma La Sapienza

Recruiting

Rediscovering Biomarkers for the Diagnosis and Early Treatment Response in NEN (REBORN) (REBORN)

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Neoplasm | Neuroendocrine Tumor Grade 2 | Neuroendocrine Tumor Grade 1

Italy
Peking Union Medical College Hospital

Recruiting

First- Line Treatment With Durvalumab Plus XELOX Chemotherapy in Advanced Gastrointestinal Neuroendocrine Carcinoma

Gastrointestinal Neuroendocrine Carcinoma

China
Nanjing Leads Biolabs Co.,Ltd

Recruiting

A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma

Advanced Neuroendocrine Carcinoma

China
Tianjin Medical University Cancer Institute and...

Recruiting

Clinical Study of Surufatinib Plus Sintilimab Combined With Chemotherapy in the Treatment of Advanced Gastric Neuroendocrine Carcinoma

Gastric Neuroendocrine Carcinoma

China
Hutchison Medipharma Limited

Recruiting

A Phase 3 Study to Evaluate Surufatinib Plus Toripalimab in the Treatment of Advanced Neuroendocrine Carcinoma

Advanced Neuroendocrine Carcinoma

China
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

Gastric Neuroendocrine Carcinoma | Intestinal Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Carcinoma

United States
University of Western Ontario, Canada

Completed

Evaluation of Methods for the Determination of Chromogranin A in Routine Blood Samples

Neuroendocrine Carcinoma (Carcinoid)

Canada
University of Iowa
Patient-Centered Outcomes Research Institute; Medical University of South Carolina and other collaborators

Enrolling by invitation

Neuroendocrine Tumors - Patient Reported Outcomes (NET-PRO)

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Lung Neuroendocrine Neoplasm | Gastroenteropancreatic Neuroendocrine Tumor

United States
National Cancer Institute (NCI)

Recruiting

Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas

Neuroendocrine Tumors | Carcinoma, Neuroendocrine | Neuroendocrine Carcinomas | Carcinoma, Adrenal Cortical | Carcinoma, Adrenocortical

United States
Shanghai Chest Hospital

Unknown

Optimization for the Treatment of Advanced Pulmonary Large Cell Neuroendocrine Carcinoma

Pulmonary Large Cell Neuroendocrine Carcinoma
M.D. Anderson Cancer Center

Active, not recruiting

Phase II Study of AK104 (Cadonilimab) for Recurrent Small Cell Neuroendocrine Carcinomas of the Cervix

Cervical Cancer | Cervix Cancer | Carcinomas

United States
Charles Kunos
National Center for Advancing Translational Sciences (NCATS)

Completed

Next Generation Sequencing-Based Stratification of Front Line Treatment of HighGrade Neuroendocrine Carcinoma (PRECISION-NEC)

Large-Cell Neuroendocrine Carcinoma

United States
University of California, San Francisco
Merck Sharp & Dohme LLC

Completed

Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine Carcinomas

High Grade Malignant Neuroendocrine Carcinoma (Diagnosis)

United States
National Cancer Institute (NCI)

Completed

Oblimersen in Treating Patients With Merkel Cell Carcinoma

Recurrent Neuroendocrine Carcinoma of the Skin | Stage III Neuroendocrine Carcinoma of the Skin | Stage IV Neuroendocrine Carcinoma of the Skin | Stage II Neuroendocrine Carcinoma of the Skin | Stage I Neuroendocrine Carcinoma of the Skin

United States
H. Lee Moffitt Cancer Center and Research Institute
Merck Sharp & Dohme LLC

Active, not recruiting

Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Neuroendocrine Cancer

United States
National Cancer Institute (NCI)

Completed

Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery

Refractory Pancreatic Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Tumor G1 | Pancreatic Neuroendocrine Tumor G2

United States
Wren Laboratories LLC

Enrolling by invitation

RegisterNET - A Registry for Neuroendocrine Tumors in the USA (RegisterNET)

Neuroendocrine Tumor | Neuroendocrine Carcinoma | Carcinoid

United States
National Cancer Institute (NCI)

Completed

S0331: Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer

Recurrent Neuroendocrine Carcinoma of the Skin | Stage III Neuroendocrine Carcinoma of the Skin | Stage II Neuroendocrine Carcinoma of the Skin

United States
AbbVie

Terminated

Rovalpituzumab Tesirine in Delta-Like Protein 3-Expressing Advanced Solid Tumors

Glioblastoma | Medullary Thyroid Cancer | Malignant Melanoma | Other Solid Tumors | Large-Cell Neuroendocrine Carcinoma | Neuroendocrine Prostate Cancer | High Grade Gastroenteropancreatic Neuroendocrine Carcinoma | Other Neuroendocrine Carcinoma

United States
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Recruiting

Comparing Capecitabine and Temozolomide in Combination to Lutetium Lu 177 Dotatate in Patients With Advanced Pancreatic Neuroendocrine Tumors

Metastatic Pancreatic Neuroendocrine Tumor | Unresectable Pancreatic Neuroendocrine Carcinoma

United States
Asan Medical Center

Completed

TEMCAP in Grade 3 and Low Ki-67 Gastroenteropancreatic Neuroendocrine Tumors

Neuroendocrine Tumors | Neuroendocrine Carcinoma | Capecitabine | Temozolomide

Korea, Republic of
Dwight Owen
Bristol-Myers Squibb

Active, not recruiting

Nivolumab and Temozolomide in Treating Patients With Recurrent or Refractory Small-Cell Lung Cancer or Advanced Neuroendocrine Cancer

Neuroendocrine Tumors | Small-cell Lung Cancer | Neuroendocrine Carcinoma | Large Cell Neuroendocrine Carcinoma | Lung Cancer Stage IV | Recurrent Small Cell Lung Carcinoma | Refractory Small Cell Lung Carcinoma | Metastatic Neuroendocrine Carcinoma | Grade I Neuroendocrine Carcinoma | Grade II Neuroendocrine... and other conditions

United States
European Institute of Oncology

Recruiting

PrognostIc and Predictive Factors in Unresectable Locally Advanced NEC and MANEC (NIRVANA)

Neuroendocrine Carcinoma

Italy
Peking Union Medical College Hospital
Harbin Medical University; The First Affiliated Hospital of Xiamen University

Recruiting

Chidamide Plus Etoposide and Cisplatin/Carboplatin as First-line Treatment for Extrapulmonary Neuroendocrine Carcinoma

Neuroendocrine Tumors | Neuroendocrine Carcinoma

China
H. Lee Moffitt Cancer Center and Research Institute
Advanced Accelerator Applications

Recruiting

Use of 68Ga-dotatate PET Scan in Neuroendocrine Carcinoma of the GI Tract

Neuroendocrine Carcinoma

United States
Intergroupe Francophone de Cancerologie Thoracique
Federation Francophone de Cancerologie Digestive; GERCOR - Multidisciplinary...

Active, not recruiting

Nivolumab +/- Ipilimumab in Patients With Advanced, Refractory Pulmonary or Gastroenteropancreatic Poorly Differentiated Neuroendocrine Tumors (NECs) (NIPINEC)

Neuroendocrine Carcinoma

France

Clinical Trials on Neuroendocrine Carcinomas

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations